ALK and non-small cell lung carcinoma: The BRAVE study investigated how to select first‐line treatment based on testing of EGFR, ALK, ROS1, and PD‐L1 in nonsquamous NSCLC patients in 11 medical centers in Japan and showed that, while 197 of 202 patients (97.5%) were tested for EGFR, only 39.1% were concurrently tested for all three genomic biomarkers.19